10-Q: Nevro Corp. Reports First Quarter 2024 Results, Revenue Up 6% Year-Over-Year

Nevro Corp. announced its first quarter 2024 financial results, showing a 6% increase in revenue compared to the same period last year, driven by growth in the U.S. market and the inclusion of SI Joint product revenue.

Summary

• Nevro Corp.'s revenue for the first quarter of 2024 reached $101.9 million, a 6% increase from $96.3 million in the first quarter of 2023.
• U.S. revenue grew by 6% to $87.0 million, while international revenue increased to $14.9 million.
• The company's gross profit increased by 11% to $71.5 million, with a gross margin of 70%, up from 67% in the prior year.
• Operating expenses totaled $107.4 million, including $14.8 million in research and development and $88.3 million in sales, general, and administrative costs.
• Nevro reported a net loss of $25.4 million, or $0.70 per share, compared to a net loss of $35.0 million, or $0.98 per share, in the first quarter of 2023.
• The company's cash, cash equivalents, and short-term investments totaled $281.5 million as of March 31, 2024.
• A restructuring plan was approved on May 5, 2024, which is expected to incur a $4 million to $5 million charge in the second quarter of 2024.

Sentiment

Score: 5

Explanation: The document presents mixed results. While revenue growth and improved gross margin are positive, the net loss and planned restructuring are concerning. The company's future success depends on its ability to manage costs, expand market share, and achieve profitability.

Positives

• Revenue increased by 6% year-over-year, indicating growth in sales.
• Gross margin improved to 70%, suggesting better cost management.
• Net loss decreased from $35.0 million to $25.4 million, showing progress towards profitability.
• The company has a substantial cash position of $281.5 million, providing financial stability.
• The company recorded a $13.6 million gain from the change in fair value of warrants.

Negatives

• The company reported a net loss of $25.4 million for the quarter.
• Operating expenses remain high at $107.4 million.
• The company is planning a restructuring that will incur a $4 million to $5 million charge in the next quarter.
• The company recorded a $3.5 million expense from the change in fair value of contingent consideration.

Risks

• The company's business is subject to macroeconomic conditions, including inflation, interest rates, and supply chain issues.
• The company relies on third-party suppliers, which exposes it to supply chain risks.
• The company is subject to the risk of inventory obsolescence and expiration.
• The company's ability to grow revenue depends on physician awareness and acceptance of its products.
• Reimbursement and coverage decisions by third-party payors can impact the company's revenue.
• The company faces significant competition in the neuromodulation market.
• The company may need to raise additional funds in the future, which may not be available on acceptable terms.

Future Outlook

The company expects its cash and cash equivalents, along with anticipated funds from receivables, to be sufficient to fund operations for at least the next 12 months. They plan to continue investing in sales, R&D, and clinical trials. The company may also seek additional funding through equity or debt financings.

Management Comments

• Management believes the superiority of 10 kHz Therapy over traditional SCS therapies will allow them to expand in the global SCS market.
• Management intends to continue to make significant investments in the sales organization, in research and development (R&D), and in conducting clinical trials to support future regulatory submissions.
• Management believes expanding into new indications, implementing product improvements and continuing to demonstrate the efficacy, safety and cost effectiveness of the 10 kHz Therapy through clinical data are all critical to increasing the adoption of this therapy.

Industry Context

The company operates in the neuromodulation market, which is dominated by large players like Medtronic, Boston Scientific, and Abbott Laboratories. Nevro is focused on differentiating itself through its proprietary 10 kHz Therapy and expanding into new indications like PDN and NSBP. The acquisition of Vyrsa also allows Nevro to expand its chronic pain portfolio.

Comparison to Industry Standards

• Nevro's 6% revenue growth is a positive sign, but it is important to compare this to the growth rates of its competitors like Medtronic, Boston Scientific, and Abbott in their respective neuromodulation divisions.
• The gross margin of 70% is a key metric to watch, as it indicates the company's ability to control manufacturing costs. It should be compared to the gross margins of its competitors to assess its competitiveness.
• The net loss of $25.4 million is a concern, and it is important to see how this compares to the profitability of its competitors. Companies like Medtronic and Boston Scientific are generally profitable, so Nevro needs to demonstrate a clear path to profitability.
• Nevro's focus on clinical trials and data to support its 10 kHz Therapy is a key differentiator, and the results of these trials should be compared to the clinical data of competing therapies.
• The company's cash position of $281.5 million is a positive, but it is important to assess how this compares to the cash reserves of its competitors and whether it is sufficient to fund its growth plans.

Legal Proceedings

• The company is involved in various legal proceedings, including patent oppositions at the European Patent Office (EPO) initiated by competitors.
• The company is also involved in other legal proceedings, such as employment matters, product liability matters, and professional liability matters.
• The company is cooperating with a civil investigative demand (CID) from the United States Attorneys Office for the Northern District of California related to its spinal cord stimulation system (SCS System).
• An arbitration ruling on April 8, 2024, required Flathead Partners to transfer control of a patent application back to the company and concluded that Nevro did not owe Flathead Partners royalties.

Stakeholder Impact

• Shareholders may be concerned about the net loss and the need for potential future capital raises.
• Employees may be affected by the restructuring plan.
• Customers and patients may benefit from the company's continued investment in product development and clinical trials.
• Suppliers may be impacted by the company's supply chain management and minimum purchase commitments.
• Creditors may be impacted by the company's debt obligations and ability to repay its loans.

Next Steps

• The company will continue to invest in sales, R&D, and clinical trials.
• The company will implement a restructuring plan expected to be completed by the end of the second quarter of 2024.
• The company will continue to seek expanded payor coverage for its therapies.
• The company will monitor and respond to macroeconomic conditions.

Key Dates

Keywords

spinal cord stimulation, neuromodulation, chronic pain, HFX, Senza, 10 kHz Therapy, PDN, NSBP, SI Joint, medical device